Aurobindo’s acquisition of 15 brands from Pfizer and Viatris to gain entry to Indonesia marks a role reversal of sorts as Pfizer has been licensing generics from Aurobindo. Scrip takes a look at some of the opportunities and challenges in this growing Southeast Asian market.
Aurobindo's Entry Into Indonesia Shows Growing Potential Of SE Asia • Source: Shutterstock
Aurobindo Pharma Limited’s recently announced acquisition of 15 undisclosed branded products in Indonesia for $48m in cash from Pfizer Inc. and Viatris Inc. marks an interesting role reversal of sorts.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.
